Alnylam Pharmaceuticals continues to lead in RNAi therapeutics with a standout quarter!

July 31, 2025 · Business Wire

Alnylam Pharmaceuticals Reports Second Quarter 2025 Financial Results

Alnylam reported strong growth in its TTR franchise, driven by the first full quarter of AMVUTTRA sales in ATTR-CM, and raised its full-year 2025 guidance.

• Total net product revenues of $672 million, up 64% from Q2 2024
• TTR net product revenues of $544 million, up 77%
• Approximately 1,400 ATTR-CM patients on AMVUTTRA as of June 30, 2025
• 2025 total net product revenue guidance raised to $2.65–$2.8 billion

Read the full release

Source: Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), via Business Wire. Figures are as reported on the release date; guidance is forward-looking and subject to the risks described in the full release.